Intra-Cellular's CAPLYTA (lumateperone) Receives the US FDA's Approval for the Treatment of Schizophrenia in Adults
Shots:
- The approval is based on the study assessing CAPLYTA (42 mg) vs PBO while keeping Positive and Negative Syndrome Scale (PANSS) as 1EP
- The study resulted in somnolence/sedation (24% vs.10%) and dry mouth (6% vs. 2%)
- CAPLYTA is a once-daily- oral therapy mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors
Click here to read full press release/ article | Ref: Intra-Cellular | Image: Behance
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.
